Liprolog Mix50 (Insulin Lispro)

Insulin lispro mimics natural insulin by binding to insulin receptors on muscle, fat, and liver cells. This activates signaling pathways that promote glucose uptake and storage while inhibiting hepatic glucose production, resulting in a rapid reduction of circulating blood glucose after meals.

The dose of Liprolog Mix50 is individualized by the prescribing healthcare professional based on factors such as age, weight, renal function, dietary intake, and current glycemic control. Patients should follow the prescriber’s instructions and adjust only under medical supervision.

Insulin lispro is classified as a pregnancy‑category drug where the benefits may outweigh potential risks. It is commonly used when tight glycemic control is needed during pregnancy. Breastfeeding mothers should consult their physician, as insulin does pass into milk in small amounts but is generally considered compatible.

To order Liprolog Mix50, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Liprolog Mix50 (insulin lispro) has a rapid onset of action, typically within 10–15 minutes, and a short duration of about 3–5 hours, similar to other rapid‑acting analogs such as insulin aspart and insulin glulisine. Choice among them often depends on physician preference, patient response, and formulary considerations.

Liprolog Mix50 should be stored in a refrigerator at 2–8 °C, protected from light, and must not be frozen or shaken. Once in use, it may be kept at controlled room temperature (up to 30 °C) for a limited period as indicated on the label, but refrigeration is preferred for stability.

Liprolog Mix50 is administered by subcutaneous injection, usually into the abdomen, thigh, or upper arm. The injection should be given shortly before meals, and the exact timing and site rotation are determined by the prescriber to optimize glucose control and reduce injection‑site reactions.

The most serious risks include severe hypoglycemia, which can cause seizures or loss of consciousness, and rare allergic reactions such as anaphylaxis. Patients should be educated on recognizing early signs of hypoglycemia and instructed to seek immediate medical attention for any severe allergic symptoms.

Liprolog Mix50 is contraindicated in individuals with a known hypersensitivity to insulin lispro or any of its excipients. It should also be avoided in patients with severe hypoglycemia unawareness until the condition is managed, and in those for whom rapid‑acting insulin is not appropriate as determined by a healthcare professional.